Pramlintide
Also known as: Symlin, Amylin analog
An amylin analog that slows gastric emptying and promotes satiety. FDA-approved for diabetes; studied for weight loss and metabolic control.
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in 30-50% of users during the first 1-2 weeks of therapy. Usually resolves spontaneously as tolerance develops. Eating smaller meals and avoiding high-fat foods may help. If severe, dose titration can be slowed.
Reported in 5-10% of users, typically during initial titration. Usually resolves within 1-2 weeks. Slower titration schedules may reduce incidence.
Risk is highest during the first 2-4 weeks of therapy. Insulin doses typically require reduction of 10-50% when pramlintide is initiated. Patients must monitor blood glucose closely and be trained to recognize and treat hypoglycemia. Pramlintide itself does not cause hypoglycemia but enhances insulin's glucose-lowering effect.
Occurs in 1-5% of users. Usually mild and transient. Proper site rotation and injection technique minimize risk. Ensure skin is completely dry before injection.
Reported in 2-5% of users. Usually mild and self-resolving. May be related to initial metabolic changes or dehydration.
Occurs in 1-3% of users, often related to hypoglycemia or rapid blood glucose changes. Ensure adequate carbohydrate intake and monitor blood glucose.
Reported in 2-5% of users. Usually mild and transient. May be related to slowed gastric emptying. Eating smaller, more frequent meals may help.
Extremely rare (<0.1% of users). Symptoms include difficulty breathing, swelling of face/throat, severe rash, or rapid heartbeat. Seek emergency medical attention immediately. Pramlintide is contraindicated in patients with known hypersensitivity to pramlintide or any component of the formulation.
Very rare but documented in post-marketing surveillance. Symptoms include severe abdominal pain, elevated amylase/lipase, and nausea. Seek immediate medical evaluation if severe abdominal pain develops. Pramlintide is contraindicated in patients with a history of pancreatitis.
Pramlintide slows gastric emptying and is contraindicated in patients with severe gastroparesis. Use with caution in patients with mild-to-moderate gastroparesis. Monitor for worsening symptoms such as persistent nausea, vomiting, or abdominal bloating.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 15-120 mcg |
| Frequency | 3x daily with meals |
| Timing | Immediately before major meals (breakfast, lunch, dinner) |
| Route | Subcutaneous |
FDA-approved dosing starts at 15 mcg and titrates by 15 mcg increments every 3 days to target dose of 30-60 mcg per meal. Maximum 120 mcg per injection. For research purposes, follow clinical titration protocols to assess tolerability.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 3949 Da |
| Half-life | 48 minutes (subcutaneous) |
| Sequence | KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY |
Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin that regulates postprandial glucose excursions. It acts on amylin receptors in the brain and gastrointestinal tract to slow gastric emptying, suppress glucagon secretion, and promote satiety, thereby reducing postprandial blood glucose spikes and overall caloric intake. These effects complement insulin action and improve glycemic control in both type 1 and type 2 diabetes.
Amylin Receptor Signaling
Pramlintide binds to amylin receptors (calcitonin receptor-like receptor with receptor activity-modifying protein) in the hypothalamus and brainstem, triggering satiety signals and reducing appetite-stimulating neuropeptide Y release.
Gastric Emptying Inhibition
Activation of amylin receptors in the gastric antrum and pylorus slows the rate at which food moves from the stomach into the small intestine, reducing the rate of nutrient absorption and postprandial glucose spikes.
Glucagon Suppression
Pramlintide inhibits glucagon secretion from pancreatic alpha cells in the fed state, preventing hepatic glucose production and further reducing postprandial hyperglycemia.
Caloric Intake Reduction
Enhanced satiety signaling and delayed gastric emptying lead to reduced meal size and overall daily caloric intake, supporting modest weight loss in some patients.
- Pramlintide is a 37-amino-acid peptide that mimics the structure and function of endogenous amylin
- It is the only amylin analog approved by the FDA for diabetes management
- Pramlintide does not increase insulin secretion — it works synergistically with insulin to improve glucose control
- Nausea is common during initial titration but typically resolves within 1-2 weeks as the body adapts
- Pramlintide reduces the risk of severe hypoglycemia when used with insulin by suppressing glucagon and slowing nutrient absorption
Track your Pramlintide research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Pramlintide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.